de Guglielmo Giordano, Martin-Fardon Rémi, Teshima Koji, Ciccocioppo Roberto, Weiss Friedbert
Molecular and Cellular Neuroscience Department, The Scripps Research Institute, La Jolla, CA, USA.
School of Pharmacy, Pharmacology Unit, University of Camerino, Italy.
Addict Biol. 2015 Jul;20(4):643-51. doi: 10.1111/adb.12157. Epub 2014 Jun 16.
Dysregulation of the nociceptin (N/OFQ) system has been implicated in alcohol abuse and alcoholism, and growing evidence suggests that targeting this system may be beneficial for treating alcoholism. To further explore the treatment target potential of the N/OFQ system, the novel non-peptide, small-molecule N/OFQ (NOP) agonist MT-7716, (R)-2-{3-[1-(Acenaphthen-1-yl)piperidin-4-yl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-N-methylacetamide hydrochloride hydrate, was examined for its effects on ethanol self-administration and stress-induced reinstatement of alcohol seeking in non-dependent and post-dependent rats. Male Wistar rats were trained to self-administer ethanol and then made ethanol dependent via repeated intragastric ethanol intubation. The effects of MT-7716 (0.3 and 1 mg/kg; PO) on alcohol self-administration were determined 2 weeks following dependence induction, when baseline self-administration was restored. Effects of MT-7716 on stress-induced reinstatement were tested in separate cohorts of rats, 1 and 3 weeks post-withdrawal. MT-7716 reduced alcohol self-administration and stress-induced reinstatement of alcohol seeking in post-dependent rats, but was ineffective in non-dependent animals. Moreover, the prevention of stress-induced reinstatement by MT-7716 was more pronounced at 3 weeks post-dependence. The results further confirm treatment target potential for the NOP receptor and identify non-peptide NOP agonists as promising potential treatment drugs for alcohol abuse and relapse prevention. The findings also support dysregulation of the N/OFQ system as a factor in alcohol seeking and reinforcement.
伤害感受素(N/OFQ)系统失调与酒精滥用和酒精中毒有关,越来越多的证据表明,针对该系统可能有助于治疗酒精中毒。为了进一步探索N/OFQ系统的治疗靶点潜力,研究了新型非肽小分子N/OFQ(NOP)激动剂MT-7716,即(R)-2-{3-[1-(苊-1-基)哌啶-4-基]-2-氧代-2,3-二氢-1H-苯并咪唑-1-基}-N-甲基乙酰胺盐酸盐水合物,对非依赖和戒断后大鼠乙醇自我给药及应激诱导的觅酒行为恢复的影响。雄性Wistar大鼠经训练自我给药乙醇,然后通过重复胃内插管使其对乙醇产生依赖。在诱导依赖2周后,当基线自我给药恢复时,测定MT-7716(0.3和1mg/kg;口服)对酒精自我给药的影响。在戒断后1周和3周的不同大鼠组中测试MT-7716对应激诱导恢复的影响。MT-7716减少了戒断后大鼠的酒精自我给药及应激诱导的觅酒行为恢复,但对非依赖动物无效。此外,MT-7716对应激诱导恢复的预防作用在戒断后3周更为明显。这些结果进一步证实了NOP受体的治疗靶点潜力,并确定非肽NOP激动剂是酒精滥用和预防复发的有前景的潜在治疗药物。这些发现还支持N/OFQ系统失调是觅酒和强化行为的一个因素。